These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 35616802)

  • 41. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.
    Yu W; Wu X; Ren J; Zhang X; Wang Y; Li C; Xu W; Li J; Li G; Zheng W; Liao H; Yuan X
    Comb Chem High Throughput Screen; 2021; 24(7):1069-1082. PubMed ID: 33106140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
    Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
    Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell entry mechanisms of SARS-CoV-2.
    Shang J; Wan Y; Luo C; Ye G; Geng Q; Auerbach A; Li F
    Proc Natl Acad Sci U S A; 2020 May; 117(21):11727-11734. PubMed ID: 32376634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
    Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
    MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of a Series of Neutralizing Nanobodies against SARS-CoV-2 Spike Protein].
    Zhuchkov VA; Ivanov SV; Kravchenko JE; Chumakov SP
    Mol Biol (Mosk); 2023; 57(3):505-516. PubMed ID: 37326055
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
    Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.
    Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF
    J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computational design of scFv anti-receptor binding domain of SARS-CoV-2 spike protein based on antibody S230 anti-SARS-CoV-1.
    Firdaus ARR; Baroroh U; Ramdani Tohari T; Hardianto A; Subroto T; Yusuf M
    J Biomol Struct Dyn; 2024; 42(1):22-33. PubMed ID: 37880854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generation and Characterization of a Nanobody Against SARS-CoV.
    Li JF; He L; Deng YQ; Qi SH; Chen YH; Zhang XL; Hu SX; Fan RW; Zhao GY; Qin CF
    Virol Sin; 2021 Dec; 36(6):1484-1491. PubMed ID: 34403037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
    Hua RH; Zhang SJ; Niu B; Ge JY; Lan T; Bu ZG
    Microbiol Spectr; 2023 Aug; 11(4):e0119023. PubMed ID: 37306579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
    Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ
    Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
    Huang KA; Chen X; Mohapatra A; Nguyen HTV; Schimanski L; Tan TK; Rijal P; Vester SK; Hills RA; Howarth M; Keeffe JR; Cohen AA; Kakutani LM; Wu YM; Shahed-Al-Mahmud M; Chou YC; Bjorkman PJ; Townsend AR; Ma C
    Nat Commun; 2023 Jan; 14(1):311. PubMed ID: 36658148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.
    Greaney AJ; Starr TN; Gilchuk P; Zost SJ; Binshtein E; Loes AN; Hilton SK; Huddleston J; Eguia R; Crawford KHD; Dingens AS; Nargi RS; Sutton RE; Suryadevara N; Rothlauf PW; Liu Z; Whelan SPJ; Carnahan RH; Crowe JE; Bloom JD
    Cell Host Microbe; 2021 Jan; 29(1):44-57.e9. PubMed ID: 33259788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.